BSGM to Evaluate Patients With GI Symptoms
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Body surface gastric mapping device.
- Who it may be relevant to
- Registry conditions: Gastrointestinal Motility Disorders in Children, Functional Gastrointestinal Disorders, Gastroparesis, Dyspepsia and Other Specified Disorders of Function of Stomach. Basic parameters: 8 years — 25 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Body Surface Gastric Mapping (BSGM) to Evaluate Patients With Gastrointestinal (GI) Symptoms
Overview
The goal of this observational study is to learn about gastric myoelectric activity in children with GI symptoms. The main question it aims to answer is which patterns or signals are associated with GI symptoms as measured by a body surface gastric mapping (BSGM) device. Participants will have their stomach activity recorded for up to 4 hours using the BSGM device and log real-time symptoms. Researchers will compare the recordings of healthy children and children with GI symptoms to define abnormal GI patterns.
Detailed description
This is an prospective, multi-cohort study that will focus on adaptation and optimization of a novel non-invasive device called 'Body Surface Gastric Mapping (BSGM)' for use in children including defining and optimizing normal ranges in healthy children, defining abnormal patterns in children with GI symptoms, comparing BSGM patterns with currently used diagnostic tests, and evaluating the mechanisms behind current therapeutic interventions using BSGM patterns as biomarkers.
Interventions
- Device Body surface gastric mapping device
A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
Primary outcome measures
- BSGM pediatric reference ranges in healthy controls. [Time frame: 30 minutes before the meal and 4 hours after having meal.]
Secondary outcome measures (12)
- Abnormal BSGM patterns in participants with functional GI disorders. [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Functional disability: Functional disability will be measured by child-reported responses to questions on the Functional Disability Inventory (FDI). [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Nausea Severity [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Abdominal Pain Severity [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Quality of Life - PROMIS-25 Instrument [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Quality of Life - PAGI-QoL [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Quality of life - Pediatric Quality of Life Modules [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Compare pediatric BSGM patterns with gastric scintigraphy, a reference diagnostic test. [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Compare BSGM metrics with the antroduodenal manometry (ADM) metrics. [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Changes in BSGM patterns after heart rate variability biofeedback (HRVB) sessions. [Time frame: Baseline visit before HRVB and two weeks after HRVB.]]
- Changes in BSGM patterns after percutaneous electrical nerve field stimulation (PENFS). [Time frame: 30 minutes before the meal and 4 hours after having meal.]
- Changes in BSGM patterns after pyloric Botulinum toxin (Botox) injection. [Time frame: 30 minutes before the meal and 4 hours after having meal.]
Eligibility criteria
Inclusion Criteria for Cases
- Males or females age 8 to 25 years.
- Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.
- Confirmed diagnosis of a Functional Gastrointestinal and/or Motility Disorder OR undergoing one of the following procedures as part of their clinical care at one of the participating centers:
- HRVB
- PENFS
- ADM
- Colonic Manometry
- Pyloric Botox
- Pyloric Dilation
- Gastric Scintigraphy
- GES
- gammaCore
- Those with a body mass index of < 35.
- Parental/guardian permission (informed consent) and if appropriate, child assent.
Exclusion Criteria for Cases
- History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin. (Please note, majority of feeding tubes can be accommodated by the array placement.)
- Pregnant women.
- Those with any condition, where fasting is not recommended by a physician.
- Any allergies to foods that may be present in the standardized meal that cannot be accommodated with an acceptable substitute meal.
- Those with physical limitations, who are not able to maintain a relaxed reclined position for the study visit duration.
- Those with major developmental delay or cognitive impairment, who are not able to report their symptoms/feelings in the questionnaires.
- Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Inclusion Criteria for Controls
- Males or females age 8 to 25 years.
- Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.
- Do not have an active Functional Gastrointestinal disorder (FGID) diagnosis and will not be undergoing any procedures outlined in the recruitment plan in the near future.
- Those with a body mass index of < 35.
- Individuals may include siblings of those with FGIDs.
- Parental/guardian permission (informed consent) and if appropriate, child assent.
Exclusion Criteria for Controls
- History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin.
- Pregnant women.
- Those with any condition, where fasting is not recommended by a physician.
- Allergies to foods that may be included in the standardized meal that cannot be accommodated with an acceptable substitute meal.
- Those with physical limitations, who are not able to maintain a relaxed reclined position for the study duration.
- Those with major developmental delay or cognitive impairment, who are not able to report their symptoms/feelings in the questionnaires.
- Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 5 centers
- Alliant International University — San Diego
- Children's Mercy Hospital — Kansas City
- Cincinnati Children's Hospital Medical Center — Cincinnati
- Nationwide Children's Hospital — Columbus
- Children's Hospital of Philadelphia — Philadelphia
Identifiers
NCT: NCT05880199 · 21-018520